Evidence map›Paper›PMID 39901360›Full record

ArticlePharmacoepidemiology and drug safety2025

Evaluating the Accuracy of Responses by Large Language Models for Information on Disease Epidemiology.

Kexin Zhu, Jiajie Zhang, Anton Klishin, Mario Esser, William A Blumentals, Juhaeri Juhaeri, Corinne Jouquelet-Royer, Sarah-Jo Sinnott

Abstract read
In one paragraph

Article in Pharmacoepidemiology and drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kexin ZhuEpidemiology and Benefit Risk, Sanofi, Bridgewater, New Jersey, USA.
Jiajie ZhangBabraham Research Campus, Sanofi, Cambridge, UK.
Anton KlishinGlobal Pharmacovigilance, Sanofi, Warsaw, Poland.
Mario EsserGlobal Pharmacovigilance, Sanofi, Frankfurt, Germany.
William A BlumentalsEpidemiology and Benefit Risk, Sanofi, Cambridge, Massachusetts, USA.
Juhaeri JuhaeriEpidemiology and Benefit Risk, Sanofi, Bridgewater, New Jersey, USA.
Corinne Jouquelet-RoyerGlobal Pharmacovigilance, Sanofi, Paris, France.
Sarah-Jo SinnottEpidemiology and Benefit Risk, Sanofi, Cambridge, Massachusetts, USA.

Funding

Sanofi
6 · The paper itself

Abstract

purposeAccurate background epidemiology of diseases are required in pharmacoepidemiologic research. We evaluated the performance of large language models (LLMs), including ChatGPT-3.5, ChatGPT-4, and Google Bard, when prompted with questions on disease frequency.

methodsA total of 21 questions on the prevalence and incidence of common and rare diseases were developed and submitted to each LLM twice on different dates. Benchmark data were obtained from literature searches targeting "gold-standard" references (e.g., government statistics, peer-reviewed articles). Accuracy was evaluated by comparing LLMs' responses to the benchmark data. Consistency was determined by comparing the responses to the same query submitted on different dates. The relevance and authenticity of references were evaluated.

resultsThree LLMs generated 126 responses. In ChatGPT-4, 76.2% of responses were accurate, which was higher compared to 50.0% in Bard and 45.2% in ChatGPT-3.5. ChatGPT-4 exhibited higher consistency (71.4%) than Bard (57.9%) or ChatGPT-3.5 (46.7%). ChatGPT-4 provided 52 references with 27 (51.9%) providing relevant information, and all were authentic. Only 9.2% (10/109) of references from Bard were relevant. Of 65/109 unique references, 67.7% were authentic, 7.7% provided insufficient information for access, 10.8% provided inaccurate citation, and 13.8% were non-existent/fabricated. ChatGPT-3.5 did not provide any references.

conclusionsChatGPT-4 outperformed in retrieving information on disease epidemiology compared to Bard and ChatGPT-3.5. However, all three LLMs presented inaccurate responses, including irrelevant, incomplete, or fabricated references. Such limitations preclude the utility of the current forms of LLMs in obtaining accurate disease epidemiology by researchers in the pharmaceutical industry, in academia, or in the regulatory setting.

Indexed as

PharmacoepidemiologyHumansIncidenceLarge Language ModelsPrevalenceartificial intelligenceChatGPTGoogle Bardlarge language modelpharmacoepidemiology

Identifiers

PMID39901360
PMCPMC11791122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.